Patents by Inventor Harish C. Joshi
Harish C. Joshi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8889705Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are noscapine analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. While the antitussive plant alkaloid, noscapine, binds tubulin, displays anticancer activity, and has a safe pharmacological profile in humans, structure-function analyzes pointed to a proton at position 9 of the isoquinoline ring that can be modified without compromising tubulin binding activity. Noscapine analogs with various functional moieties at position 9 on the isoquinoline ring kill human cancer cells resistant to other anti-microtubule agents, such as vincas and taxanes.Type: GrantFiled: June 5, 2012Date of Patent: November 18, 2014Assignee: Emory UniversityInventors: Harish C. Joshi, Ritu Aneja, Surya N. Vangapandu
-
Patent number: 8815835Abstract: 9-aminonoscapine, prodrugs thereof, and pharmaceutically acceptable salts thereof, are disclosed. Pharmaceutical compositions including 9-aminonoscapine, and methods of preparation and use thereof are disclosed. 9-aminonoscapine is a noscapine analog that can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, by binding tubulin and inducing apoptosis selectively in tumor cells (ovarian and T-cell lymphoma) resistant to paclitaxel, vinblastine and teniposide. 9-aminonoscapine can perturb the progression of cell cycle by mitotic arrest, followed by apoptotic cell death associated with increased caspase-3 activation and appearance of TUNEL-positive cells. Thus, 9-aminonoscapine is a novel therapeutic agents for a variety of cancers, including ovarian and T-cell lymphoma cancers, even those that have become drug-resistant to currently available chemotherapeutic drugs.Type: GrantFiled: February 8, 2013Date of Patent: August 26, 2014Assignee: Emory UniversityInventors: Harish C. Joshi, Ritu Aneja, Surya N. Vangapandu
-
Publication number: 20130224310Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are noscapine analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. While the antitussive plant alkaloid, noscapine, binds tubulin, displays anticancer activity, and has a safe pharmacological profile in humans, structure-function analyses pointed to a proton at position 9 of the isoquinoline ring that can be modified without compromising tubulin binding activity. Noscapine analogs with various functional moieties at position 9 on the isoquinoline ring kill human cancer cells resistant to other anti-microtubule agents, such as vincas and taxanes.Type: ApplicationFiled: June 5, 2012Publication date: August 29, 2013Applicant: Emory UniversityInventors: Harish C. Joshi, Ritu Aneja, Surya N. Vangapandu
-
Patent number: 8426398Abstract: The present invention is directed to compounds which are conjugates of two non-toxic natural products, noscapine (and various noscapine analogs) and folic acid (and various folic acid analogs), where the folic acid is conjugated to noscapine or the noscapine analog at the 9-position on the isoquinoline ring on the noscapine framework. Pharmaceutical compositions including the compounds, and methods of treating various tumors using the compounds and compositions, are also disclosed. The conjugates are particularly useful for treating cancers which overexpress the Folate Receptor ? (FRa) receptor.Type: GrantFiled: January 8, 2010Date of Patent: April 23, 2013Assignee: Emory UniversityInventors: Harish C. Joshi, Surya N. Vangapandu, Ritu Aneja
-
Patent number: 8394957Abstract: 9-aminonoscapine, prodrugs thereof, and pharmaceutically acceptable salts thereof, are disclosed. Pharmaceutical compositions including 9-aminonoscapine, and methods of preparation and use thereof are disclosed. 9-aminonoscapine is a noscapine analog that can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, by binding tubulin and inducing apoptosis selectively in tumor cells (ovarian and T-cell lymphoma) resistant to paclitaxel, vinblastine and teniposide. 9-aminonoscapine can perturb the progression of cell cycle by mitotic arrest, followed by apoptotic cell death associated with increased caspase-3 activation and appearance of TUNEL-positive cells. Thus, 9-aminonoscapine is a novel therapeutic agents for a variety of cancers, including ovarian and T-cell lymphoma cancers, even those that have become drug-resistant to currently available chemotherapeutic drugs.Type: GrantFiled: September 4, 2009Date of Patent: March 12, 2013Assignee: Emory UniversityInventors: Harish C. Joshi, Ritu Aneja, Surya N. Vangapandu
-
Publication number: 20130045203Abstract: This disclosure relates to methods of treating or preventing cancer comprising administering a pharmaceutical composition comprising noscapine or noscapine derivatives to a subject diagnosed with a mutated adenomatous polyposis coli (APC) gene.Type: ApplicationFiled: February 25, 2011Publication date: February 21, 2013Applicant: EMORY UNIVERSITYInventors: Harish C. Joshi, Vincent Yang
-
Publication number: 20110294844Abstract: 9-aminonoscapine, prodrugs thereof, and pharmaceutically acceptable salts thereof, are disclosed. Pharmaceutical compositions including 9-aminonoscapine, and methods of preparation and use thereof are disclosed. 9-aminonoscapine is a noscapine analog that can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, by binding tubulin and inducing apoptosis selectively in tumor cells (ovarian and T-cell lymphoma) resistant to paclitaxel, vinblastine and teniposide. 9-aminonoscapine can perturb the progression of cell cycle by mitotic arrest, followed by apoptotic cell death associated with increased caspase-3 activation and appearance of TUNEL-positive cells. Thus, 9-aminonoscapine is a novel therapeutic agents for a variety of cancers, including ovarian and T-cell lymphoma cancers, even those that have become drug-resistant to currently available chemotherapeutic drugs.Type: ApplicationFiled: September 4, 2009Publication date: December 1, 2011Applicant: EMORY UNIVERSITYInventors: Harish C. Joshi, Ritu Aneja, Surya N. Vangapandu
-
Publication number: 20110286919Abstract: The present invention is directed to compounds which are conjugates of two non-toxic natural products, noscapine (and various noscapine analogs) and folic acid (and various folic acid analogs), where the folic acid is conjugated to noscapine or the noscapine analog at the 9-position on the isoquinoline ring on the noscapine framework. Pharmaceutical compositions including the compounds, and methods of treating various tumors using the compounds and compositions, are also disclosed. The conjugates are particularly useful for treating cancers which overexpress the Folate Receptor ? (FRa) receptor.Type: ApplicationFiled: January 8, 2010Publication date: November 24, 2011Applicant: EMORY UNIVERSITYInventors: Harish C. Joshi, Surya N. Vangapandu, Ritu Aneja
-
Publication number: 20100227878Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are noscapine analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. While the antitussive plant alkaloid, noscapine, binds tubulin, displays anticancer activity, and has a safe pharmacological profile in humans, structure-function analyses pointed to a proton at position 9 of the isoquinoline ring that can be modified without compromising tubulin binding activity. Noscapine analogs with various functional moieties at position 9 on the isoquinoline ring kill human cancer cells resistant to other anti-microtubule agents, such as vincas and taxanes. Representative analogs include the 9-nitro, 9-bromo-, 9-iodo-, and 9-fluoro-noscapines, which bind tubulin and induce apoptosis selectively in tumor cells (ovarian and T-cell lymphoma) resistant to paclitaxel, vinblastine and teniposide.Type: ApplicationFiled: March 4, 2008Publication date: September 9, 2010Applicant: EMORY UNIVERSITYInventors: Harish C. Joshi, Ritu Aneja, Surya N. Vangapandu
-
Patent number: 6673814Abstract: The present invention relates to methods useful for the treatment of neoplastic diseases, tumor cells, and the treatment of cancer delivering compounds of the formula The invention provides various methods of delivering such compounds, combinations of treatments, and altering such compounds to enhance their effectiveness.Type: GrantFiled: January 25, 2002Date of Patent: January 6, 2004Assignee: Emory UniversityInventors: Harish C. Joshi, Keqiang Ye, Judith Kapp, Jaren Landen, David Archer, Cheryl Armstrong, Fuqiang Liu
-
Publication number: 20020137762Abstract: The present invention relates to methods useful for the treatment of neoplastic diseases, tumor cells, and the treatment of cancer delivering compounds of the formula 1Type: ApplicationFiled: January 25, 2002Publication date: September 26, 2002Inventors: Harish C. Joshi, Keqiang Ye, Judith Kapp, Jaren Landen, David Archer, Cheryl Armstrong, Fuqiang Liu
-
Patent number: 6376516Abstract: Compounds such as formula (I) are useful in the treatment of tumor cells and the treatment of cancer.Type: GrantFiled: September 26, 2000Date of Patent: April 23, 2002Assignee: Emory UniversityInventors: Harish C. Joshi, Ye Keqiang, Judith Kapp, Fuqiang Liu